What is Trodelvy™ (sacituzumab govitecan-hziy)?

Trodelvy™ (sacituzumab govitecan-hziy) is a targeted therapy for some people with metastatic triple-negative breast cancer. It is used to treat breast cancer that:1,2

  • Is hormone receptor (HR) negative and human epidermal growth factor receptor 2 (HER2) negative (also called triple-negative), and
  • Has spread to other parts of the body (metastatic), and
  • Has been previously treated with at least 2 therapies for metastatic disease

Trodelvy is the first antibody-drug conjugate (anti-Trop-2 ADC) approved by the U.S. Food & Drug Administration (FDA) specifically for the treatment of relapsed or refractory metastatic triple-negative breast cancer.1,2

Metastatic triple-negative breast cancer is an aggressive form of breast cancer with limited treatment options. Because of this, the FDA also granted Trodelvy:1,2

  • Accelerated Approval – The FDA may give accelerated approval to new drugs that treat a health condition with few or no other treatments. This means drugs like Trodelvy can be sold sooner.
  • Priority Review – The FDA can grant Priority Review when a new drug seems promising and may greatly help a disease. Priority Review means the FDA will decide whether to approve new drugs in 6 months. It is only for drugs that seem to work better or are safer than current treatments.

Chemotherapy has been the standard treatment for triple-negative breast cancer. Trodelvy offers another treatment option for people who continue to have active disease.1

What is are the ingredients in Trodelvy?

The active ingredient in Trodelvy is sacituzumab govitecan-hziy.1,2

How does Trodelvy work?

About 20 percent of breast cancer cases worldwide are triple-negative. This means it tests negative for:1

  • Estrogen receptors
  • Progesterone receptors
  • Human epidermal growth factor receptor 2 (HER2) protein

This type of cancer does not respond to hormone therapy or treatments that target HER2.

Trodelvy includes 2 parts: a monoclonal antibody and a chemotherapy drug. By combining the antibody and chemotherapy drug, the antibody portion helps to find and attach to the breast cancer cells. Once attached, the chemotherapy portion is released to attack the cancer cell.1

What are the possible side effects of Trodelvy?

The most common side effects of Trodelvy include:1,2

  • Nausea and vomiting
  • Low white blood cell counts
  • Diarrhea
  • Fatigue
  • Rash
  • Hair loss
  • Constipation
  • Decreased appetite or stomach pain
  • Low red blood cell counts

Trodelvy may also cause serious side effects, including:2

  • Severe decrease in white blood cells (neutropenia). This can lead to severe infections and include symptoms like fever, chills, cough, and shortness of breath.
  • Severe diarrhea

If you have any new or worsening signs of serious side effects, contact your doctor right away.

These are not all the possible side effects of Trodelvy. Talk to your doctor about what to expect or if you experience any changes that concern you during treatment with Trodelvy.

Things to know about Trodelvy

Before taking Trodelvy, tell your doctor if you have:1,2

  • Liver problems
  • Been told you carry a gene for uridine diphosphate-glucuronosyl transferase A1 (UGT1A1)*28. People who carry this gene have an increased risk of getting side effects with Trodelvy, especially low white blood cell counts

Trodelvy can harm an unborn baby. If you or your partner can become pregnant, you should use birth control during treatment and for some time after the last dose of Trodelvy. You should also not breastfeed during treatment with Trodelvy and for some time after the last dose. Talk to your doctor about your options for birth control and breastfeeding while taking Trodelvy.1,2

Before beginning treatment for breast cancer, tell your doctor about all your health conditions and any other drugs, vitamins, or supplements you are taking. This includes over-the-counter drugs.

For more information, read the full prescribing information of Trodelvy.

By providing your email address, you are agreeing to our privacy policy. We never sell or share your email address.

Written by: Editorial Team | Last reviewed: March 2021